chrisvoncsefalvay/vaers-outcomes huggingface dataset:
The symptoms began less than 1 minute after administration of the vaccine.  The symptoms were: throat tightness and panic, diaphoresis. They couldn't get a BP, HR 137, 100% O2 but put her on a non re-breather temp normal. No rash but was red felt like she was suffocating, grabbing at throat, nausea, difficulty verbalizing. No audible wheezing and no auscultation of her lungs. Gave epi and rapid response called.     The treatment of the reaction was:   o Antihistamines: zyrtec   o Epinephrine: x1 o transfer to the ED
Received Vaccine Monday afternoon, had high fever starting Wednesday morning (104) and even with Tylenol dosing back to back couldn't get fever under (102.7) had to administer ibuprofen as well. Starting Thursday evening bumps starting popping up all over my son. By Friday he had them on face, both arms, back of head, back, and on both legs. It is now Sunday (7/16) and he still has spots on all of these areas.
Within 24 hours of receiving dose 2 of COVID, patient experienced an enormous upswing in his tics, to the point where some of his muscles were in a clonic state. His developmental neurologist attempted to control these tics with Klonopin, with minimal success. The severity of these tics increased to the point that he experienced rhabdomyolysis. He also had an increase in intrusive thoughts, stating that he was going to die, and that he would be dead by Thanksgiving. He also was stating that he wasn't himself, he had been replaced.
A physician reported the occurrence of arthritis in a 52 year old male who was vaccinated with Lyme disease vaccine recombinant OsaP (Lymerix) for prophylaxis.  The subject's medical history, concurrent conditions and concurrent medications were not specified.  The subject received his second injection of Lymerix on an unspecified date in 1999.  The subject presented to the reporting physician in April 2000.  The physician made a diagnosis of arthritis.  He prescribed ibuprofen (Advil) and celecoxib (Celebrex), which did not provide the subject with pain relief.  The subject reported pain relief following the administration of unspecified steroids.  The arthritis persisted as of 01/07/03.  The reporting physician considered the arthritis to be possibly related to Lymerix administration.
Information has been received from a consumer who was the parent of a child who was vaccinated with mumps virus vaccine live. Subsequently the pt developed autism and developmental disability from a vaccination from an unknown vaccine. The pt was diagnosed "years ago." It was unknown if the pt sought medical attention. The pt's autism and developmental disability were considered to be other important medical events (OMIC). Additional info has been requested.
pain gets excruciating at times as flex the muscle; pain in my left calf sincethe afternoon of the vaccination; This is a spontaneous report from a contactable consumer, the patient. A 43-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: EP7553) via an unspecified route of administration in the left arm on 05Apr2021 at 12:30 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient previously received penicillin (MANUFACTURER UNKNOWN) and erythromycin (MANUFACTURER UNKNOWN) for unknown indication and unknown date and experienced drug allergy. Concomitant medications included venlafaxine hydrochloride (EFFEXOR SR), spironolactone (MANUFACTURER UNKNOWN) and birth control medicines (UNSPECIFIED) all for an unknown indication from an unknown date. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 07Apr2021 at 12:30, the patient experienced pain in left calf since the afternoon of the vaccination and the mild pain got excruciating at times as patient flexed the muscle. No therapeutic measures were taken as a result of the reported events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The clinical outcome of the events pain in left calf and pain got excruciating at times as flex the muscle was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Headache within 2 hours of administration. Body aches within 4 hours. Painful, HO swelling, that spread to within 2 inches above the elbow. Swelling is 6 inches by 8 inches.
No symptoms or side effects.  Patient lied that he never received any covid-19 vaccine before and it is his first time.  He lied about it on the form and also he said he never got it while we did the verbal screening as well.   As we entered on CAIR after he was vaccinated, we found he already had a profile on CAIR with the same name, dob, and address.  Upon calling him, he told us that he got Moderna before and because he didnt feel any side effect, and therefore he decided to get PFIZER.
Pt has complex facial and right parotid hemomyoma. Mother claims vaccinations caused increase in site of hemomyoma and due to presence of hemomyoma on jugular vein hydrocehalus.
4 hours after administration bilateral leg.thigh numbness.  Could still walk. 18 hours after administration  had severe mid back pain, that limited ability do activities.
3cm of erythema 5x9 swelling in axilla node 2 cm distal to ax @ 72 hrs post administration of vax; inflammatory react vs cellulitis
I came home with Covid; I came home with Covid; This is a spontaneous report received from a contactable reporter (Consumer or other non HCP). The reporter is the patient. A patient (no qualifiers provided) received BNT162b2 (BNT162B2), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), SUSPECTED COVID-19 (medically significant), outcome "unknown" and all described as "I came home with Covid". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Unknown results, notes: came home with Covid. Clinical course: Caller (Name withheld) called in on behalf of their mother seeking assistance for the medication Gleevec. During the call caller stated. "By the way I've taken 3 shots of your Pfizer and I think it helped me, But I just got back from a 2-week trip from (withheld), and I came home with Covid. But it's not bad, I guess my Pfizer vaccine helped me."   The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
p/vax pt devel chickenpox;it was reported that pt was exposed to sister who was never vaccinated & who devel chickenpox a wk & a half before pt did;to MD dx chickenpox;
Generalized pruritus worse on bilateral below knee legs/ankles/feet and hands including palms with erythema and raised papules. Occurred around 7 days post vaccine, still persistent post vaccine day 11.
red, swollen-site of inj size of baseball-hot;pvt MD says probably infected-cannot afford to him;larger each day0referred to city hosp
felt really hard; itching; spot on my right arm; red rash; red rash; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE INDURATION (felt really hard), VACCINATION SITE PRURITUS (itching), VACCINATION SITE RASH (spot on my right arm), VACCINATION SITE RASH (red rash) and VACCINATION SITE ERYTHEMA (red rash) in a 61-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 27-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 08-Mar-2021, the patient experienced VACCINATION SITE INDURATION (felt really hard), VACCINATION SITE PRURITUS (itching), VACCINATION SITE RASH (spot on my right arm), VACCINATION SITE RASH (red rash) and VACCINATION SITE ERYTHEMA (red rash). The patient was treated with KETOCONAZOLE at an unspecified dose and frequency. At the time of the report, VACCINATION SITE INDURATION (felt really hard), VACCINATION SITE PRURITUS (itching), VACCINATION SITE RASH (spot on my right arm), VACCINATION SITE RASH (red rash) and VACCINATION SITE ERYTHEMA (red rash) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported.
102 degrees fever; This is a spontaneous report received from a contactable reporter(s) (Other HCP) from medical information team.  A 72-year-old female patient received pneumococcal 13-val conj vac (dipht crm197 protein) (PREVNAR 13), as dose number unknown, single (Batch/Lot number: unknown) for immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: PYREXIA (non-serious), outcome "unknown", described as "102 degrees fever". Relevant laboratory tests and procedures are available in the appropriate section.  Additional information: Caller is calling in regard a patient who took the Prevnar 13 vaccine but experienced a 102 degrees fever. She wants to know if the patient can take Prevnar 20.   The information on the batch/lot number for pneumococcal 13-val conj vac (dipht crm197 protein) has been requested and will be submitted if and when received.
PATIENT WAS GIVEN 1ML DOSE INSTEAD OF 0.5ML DOSE
PATIENT WAS GIVEN PFIZER MONOVALENT VACCINE AS THE FIRST COVID VACCINE DOSE BECAUSE OUR OFFICE WAS NOT INFORMED ABOUT IT BEING DISCONTINUED. PATIENT HAD NO SIDE EFFECTS FOR 15 MINUTES AND WAS SENT HOME. SHE IS DOING FINE SO FAR, I EXPLAINED ABOUT IT TO THE MOTHER TODAY.
fever 99.8f; This case was reported by a consumer via interactive digital media and described the occurrence of fever in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   On 31st August 2020, the patient received Shingrix. On an unknown date, less than a week after receiving Shingrix, the patient experienced fever. On an unknown date, the outcome of the fever was not recovered/not resolved.   It was unknown if the reporter considered the fever to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The age group was not reported but was selected as per the vaccine indication. The patient got Shingrix shot and experienced fever 99.8 degree F. The patient asked what should he/she take.
This case was reported by a physician via a sales representative and described the occurrence of cellulitis in a 15-month-old female subject who was vaccinated with INFANRIX (GlaxoSmithKline). Concurrent vaccination included unspecified vaccines (multiple other childhood vaccines - manufacturer unspecified) given on the same date as INFANRIX. On an unspecified date the subject received unspecified dose of INFANRIX at 0.5 ml in an unknown thigh. Within a couple of days of vaccination with INFANRIX, the subject experienced cellulitis. Signs included injection site redness, hot (injection site hot to touch) and swelling. The physician considered the events were clinically significant (or requiring intervention). The subject was treated with KEFLEX. The subject resolved on therapy. Product complaint was noted. The site claimed good aseptic technique was followed and there was no change in the appearance of the vaccine administered. It was reported that cellulitis was probably related to treatment with INFANRIX. A note was made that other childhood vaccines were given at the same time, but infections have occurred only at either INFANRIX or KINRIX injection sites or that leg affected. Four subjects received INFANRIX from lot number AC14B126AA with expiration date 03 March 2013 and one subject each received KINRIX from lot number AC20B168AA with expiration date 02 December 2012 and lot number AC20B164BA with expiration 13 October 2012 (six subjects affected in total ranging in age from 15 months to 8 years). Additionally, no other subjects have received these vaccines from these lots and "not" had cellulitis with the exception of three subjects the site is still trying to locate.
persistent, inconsolabld crying x 24hr p/vax;t101.5R;
During night following injection pt developed feeling like mumps (fullness) in his throat.  No other respiratory issues.  Symptoms resolved by morning.   No medical treatment required.
flehm in throat; sneezing; sick; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCTIVE COUGH (flehm in throat), SNEEZING (sneezing) and ILLNESS (sick) in a 22-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 007c21a) for COVID-19 vaccination.     No Medical History information was reported.    On 04-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCTIVE COUGH (flehm in throat), SNEEZING (sneezing) and ILLNESS (sick). At the time of the report, PRODUCTIVE COUGH (flehm in throat), SNEEZING (sneezing) and ILLNESS (sick) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication was provided  No treatment medication was provided
BLURRED VISION; DOUBLE VISION; This spontaneous report received from a patient concerned a 52 year old female. The patient's weight, height, and medical history were not reported.  The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1805029 and expiry: 25/MAY/2021) dose was not reported, administered on 27-MAR-2021 09:30 for prophylactic vaccination. No concomitant medications were reported.  On 31-MAR-2021, the subject experienced blurred vision. On 31-MAR-2021, the subject experienced double vision. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from blurred vision, and double vision. This report was non-serious.
her arm got a little sore; This is a spontaneous report from a Pfizer sponsored program from a non-contactable consumer. A 92-year-old female patient received the first dose of BNT162B2 Pfizer-BioNTech COVID-19 mRNA Vaccine via an unspecified route of administration on 12Feb2021 (Batch/Lot number was not reported) as SINGLE DOSE for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. On an unspecified date after the first shot the patient's arm got a little sore. The event's outcome was unknown at the time of the report.  No follow-up attempts are possible. Information about lot/batch number cannot be obtained.
Nasal congestion day of administration, watery eyes the following day, mild cough 8/26/2015.
This case was reported by a nurse via call center representative and described the occurrence of rash in an elderly female patient who received SHINGRIX for prophylaxis. On an unknown date, the patient received the 2nd dose of SHINGRIX. On an unknown date, less than a year after receiving SHINGRIX, the patient experienced rash. On an unknown date, the outcome of the rash was unknown. It was unknown if the reporter considered the rash to be related to SHINGRIX. Additional details were provided as follows: This case was reported by an advanced registered nurse practitioner via chat. The age at vaccination was not reported. The healthcare professional reported that the patient developed a non-vesicular rash on her abdomen, under her breast and a little on her back after receipt of her 2nd dose of SHINGRIX. The healthcare professional did not administer the vaccine, patient got it at a pharmacy so no vaccine information was available.
This spontaneous report was received from a pharmacist and referred to a patient of unknown age and gender. On an unknown date, the patient was vaccinated with an unspecified dose of ZOSTAVAX (lot # and expiration date were not reported). The ZOSTAVAX was reconstituted with sterile diluent (manufacturer unknown). The pharmacist stated that the patient was taking valacyclovir hydrochloride (dose, frequency, route of administration, indication, lot # and expiration date were not reported) at the time, the patient was vaccinated with ZOSTAVAX.
They are very ill today; Swelling behind his ear; They are both very sore; Dizziness; Fever; Chills; This is a spontaneous report received from a contactable consumer or other non-health acre professional. A patient of unspecified age and gender received dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Batch/Lot number was not reported) via an unspecified route of administration on 11Jun2021 14:00 as 2 nd dose single for COVID-19 immunization. The patient previously received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Batch/Lot number was not reported) via an unspecified route of administration on an unspecified date as 1 st dose single for COVID-19 immunization. The patient medical history and concomitant medications were not reported. The patient experienced  very ill, swelling behind his ear, very sore, dizziness, fever and chills on 12Jun2021. The outcome of event was unknown.  Reporter was informed about Pfizer Medical Information Department and provided with the number.  Limited information was available over the call as reporter hung up abruptly. Hence, product details (NDC#, UPC#, LOT# and expiration date) and further details are unknown.  Information about lot/batch number has been requested.
pt recvd vax w/in couple of minutes c/o stomach hurting; became limp-no LOC; pale;
June 6 - developed a painful rash on the left side of my head, my left eye became very red and irritated, and I had a severe headache.  June 7 - a red bump developed on my left forehead above my eyebrow which was blistering and growing bigger. June 8 - I started experiencing continuous electrical shocks in my head causing me to twitch every few minutes. Affecting my face, ear and eye which interfered with daily activities and sleep. June 9 - I went to urgent care and was diagnosed with Hypertensive urgency and shingles (Herpes Zoster) complication and postherpetic Neuralgia. According to the physician, I had a shingles flare-up after the COVID vaccination. The vaccine was a trigger in producing an episode of shingles. I was prescribed the following medications ? clonidine (Catapres), amlodipine and valacyclovir. I was referred to an Ophthalmologist (same day) for eye examination and was started on a treatment of Prednisolone steroid drops for infection and Alfagan drops for increased eye pressure. June 11 - follow up urgent care visit, I was advised to proceed with the second Pfizer vaccine after the attending physician consulted with my primary care dr. June 19 ? Ophthalmologist visit. Continue use of eye drops 4 times per day. Following the second Pfizer vaccine, I started to experience pain in my left shoulder and a pain running from my left hip all the way down my leg. I mostly treated it by using a heating pad, ibuprofen and rest. July 7 -  follow up visit with primary care physician, he indicated that the vaccine was a likely cause of the Shingles and the other health issues I was experiencing. Advised to monitor arm pain and consider physical therapy if it doesn?t improve. July 9 - Ophthalmologist visit. Continue use of eye drops 4 times per day. Aug 18 - Ophthalmologist visit. Continue use of eye drops 4 times per day. Sep 8 - Ophthalmologist visit. Reduce use of eye drops to 2 times per day. Oct 6 - Ophthalmologist visit. Continue use of eye drops 2 times per day. Oct 13 ? follow up visit with primary care physician. Advised to continue on Amlodopine for blood pressure, and referred to Physical Therapy for arm pain Nov 11 ? started physical Therapy. Treatment ongoing with 2-3 sessions per week Nov 17 - Ophthalmologist visit. Advised to discontinue use of eyedrops and monitor redness.
I had 3 days of arm pain and fatigue following the initial injection which resolved but then 9 days later developed chills( no fever) fatigue and then the injection site became very itchy, the next day the infection site was res, painful, hard...egg sized.
Initial report received from a health care professional on 07 February 2011. An 88-year-old male patient received on 11 December 2010 a left deltoid intramuscular injection of FLUZONE HIGH-DOSE, sanofi pasteur Inc. lot number U3613AA. The patient had a history of high blood pressure and no known allergies. His concomitant medications included lisinopril and atenolol. On 12 December 2010, the patient developed a nodule on the inner side of the left arm that has been there since the day after the vaccine. The area measures 4 inches by 4 inches. The patient saw a doctor and was told to "watch it". The outcome was reported as not recovered. Follow-up information was received from a health care professional on 05 April 2011. The patient had developed an uncomplicated hematoma. The outcome remained not recovered. Follow-up information received from a health care professional on 25 April 2011. The previously reported event of hematoma was clarified by the reporter to have occurred at the injection site. The events resolved on 24 January 2011. Documents held by sender: None.
COVID-19 Breakthrough Infection while on cruise ship (very high fever 104; achy flu-like symptoms; cough).
Immediate pain throughout left arm with nerve involvement causing tingling of skin starting at shoulder, over triceps, and extending through fingers of left hand. Tingling and numbness extended up left side of neck involving left ear and left cheekbone. 12 days later pain in left shoulder is resolved but numbness and tingling still reported in left hand and left side of face.
fever; bilateral lower extremity and left arm weakness; body aches; fatigue; This case was reported by a other health professional via call center representative and described the occurrence of fever in a 40-year-old male patient who received Flu Seasonal QIV Dresden (Fluarix Tetra 2019-2020 season) (batch number T9N35, expiry date 30th June 2020) for prophylaxis.   Co-suspect products included DTPa (Reduced antigen) (Boostrix) for prophylaxis.   On 16th October 2019, the patient received Fluarix Tetra 2019-2020 season (intramuscular) .5 ml and Boostrix (intramuscular) .5 ml. On 16th October 2019, 6 hrs after receiving Fluarix Tetra 2019-2020 season and Boostrix, the patient experienced fever, weakness in extremity, general body pain and fatigue. On an unknown date, the outcome of the fever and weakness in extremity were recovered/resolved and the outcome of the general body pain and fatigue were not recovered/not resolved.   It was unknown if the reporter considered the fever, weakness in extremity, general body pain and fatigue to be related to Fluarix Tetra 2019-2020 season and Boostrix.  Additional details were provided as follows: The patient received dose of Fluarix Tetra 2019-2020 season in the left deltoid. After vaccination with dose of Fluarix Tetra 2019-2020 season and Boostrix, the patient had fever of 102 degree F. The patient stated that, till the time of reporting, recovered with fever and weakness but still had aches and fatigue. The reporter consented to follow up. There was discrepancy in outcome reported for adverse events in data base and in source document.